Thrombocytopenia due to immune destruction

Summary

Thrombocytopenia due to immune destruction (MONDO:0002048) is a disease and 253 clinical trials. Top therapeutic interventions include dexamethasone, romiplostim, and danazol. A subtype of thrombocytopenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 253

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thrombocytopenia due to immune destruction
Mondo ID	MONDO:0002048
DOID	DOID:1587
NCIT	C3991
UMLS	C0272286
MedGen	75778
GARD	0006768
Is cancer (heuristic)	no

Also known as: auto-immune thrombocytopenia · immune thrombocytopenia · thrombocytopenia due to immune destruction

Disease family

This is a subtype of thrombocytopenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood platelet disease › thrombocytopenia › thrombocytopenia due to immune destruction

Related subtypes (5): acquired thrombocytopenia, autoimmune thrombocytopenia, neonatal thrombocytopenia, thrombocytopenic purpura, inherited thrombocytopenia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 253.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	84
Not specified	64
PHASE3	49
PHASE4	15
PHASE1	15
PHASE1/PHASE2	14
EARLY_PHASE1	7
PHASE2/PHASE3	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03201848	PHASE4	ACTIVE_NOT_RECRUITING	The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia
NCT05522465	PHASE4	RECRUITING	Short-course High-dose Prednisone and Dexamethasone in Children With ITP
NCT02556814	PHASE4	COMPLETED	Caffeic Acid Combining High-dose Dexamethasone in Management of ITP
NCT02642380	PHASE4	WITHDRAWN	Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
NCT02760251	PHASE4	COMPLETED	Immunomodulation With Romiplostim in Young Adults With ITP
NCT03172676	PHASE4	UNKNOWN	Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura
NCT03229746	PHASE4	COMPLETED	Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
NCT03258866	PHASE4	COMPLETED	The Study of Different Dose Rituximab in the Treatment of ITP
NCT03771378	PHASE4	UNKNOWN	Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
NCT03866798	PHASE4	TERMINATED	Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
NCT03998982	PHASE4	UNKNOWN	Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
NCT04094805	PHASE4	UNKNOWN	A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP
NCT04102033	PHASE4	UNKNOWN	Eltrombopag in Chronic ITP
NCT04638829	PHASE4	COMPLETED	Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
NCT05311930	PHASE4	UNKNOWN	Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
NCT04562766	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04812925	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04968899	PHASE3	RECRUITING	IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
NCT05325593	PHASE3	ACTIVE_NOT_RECRUITING	Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
NCT05653219	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT06900920	PHASE3	RECRUITING	A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06962631	PHASE3	RECRUITING	V-IMMUNE® for Immune Thrombocytopenia
NCT07007962	PHASE3	RECRUITING	Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07194850	PHASE2/PHASE3	RECRUITING	A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07216079	PHASE3	ACTIVE_NOT_RECRUITING	Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
NCT07597395	PHASE3	NOT_YET_RECRUITING	ATRA for Management of Primary ITP
NCT00344149	PHASE3	COMPLETED	Rituximab as Second Line Treatment for ITP
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01763658	PHASE2/PHASE3	UNKNOWN	Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02063789	PHASE3	COMPLETED	An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
NCT02137681	PHASE3	WITHDRAWN	A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
NCT02139501	PHASE3	COMPLETED	An Investigation of rhTPO With Different Frequencies in the Management of ITP
NCT02203422	PHASE3	WITHDRAWN	A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）
NCT02270801	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy
NCT02279173	PHASE3	COMPLETED	Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
NCT02351622	PHASE3	COMPLETED	Caffeic Acid Tablets as a Second-line Therapy for ITP
NCT02391272	PHASE3	COMPLETED	A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy
NCT02649504	PHASE3	WITHDRAWN	Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	28
ROMIPLOSTIM	4	10
DANAZOL	4	9
AVATROMBOPAG	4	8
ELTROMBOPAG	4	8
EFGARTIGIMOD ALFA	4	5
ZANUBRUTINIB	4	5
FOSTAMATINIB	4	4
TERIFLUNOMIDE	4	4
LUSUTROMBOPAG	4	3
ROZANOLIXIZUMAB	4	3
TRETINOIN	4	3
BARICITINIB	4	2
TERBUTALINE	4	2
AMOXICILLIN	4	1
AZATHIOPRINE	4	1
BORTEZOMIB	4	1
CALCITRIOL	4	1
CLARITHROMYCIN	4	1
DECITABINE	4	1
HYDROXYCHLOROQUINE	4	1
IPTACOPAN	4	1
IXAZOMIB CITRATE	4	1
LACTIC ACID	4	1
LUSPATERCEPT	4	1
OSELTAMIVIR	4	1
PIRTOBRUTINIB	4	1
RITUXIMAB	4	1
UPADACITINIB	4	1
VINCRISTINE	4	1